Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: A Southwest Oncology Group study (S0012)

Marilyn L. Slovak, Victoria Bedell, Danika Lew, Kathy S. Albain, Georgiana K. Ellis, Robert B Livingston, Silvana Martino, Edith A. Perez, Gabriel N. Hortobagyi, Dorie Sher, Wendy Stock

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A serious complication associated with breast cancer treatment is the increased risk for development of therapy-related myeloid neoplasms (t-MN). To determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis, and whether detection of clonal hematopoiesis could be used as an early marker for the subsequent development of t-MN, the Southwest Oncology Group designed a pilot clonality investigation to estimate the incidence of clonal hematopoiesis during and shortly after completion of the dose-intensive neoadjuvant regimens for high-risk breast cancer patients. Peripheral blood samples from 274 patients obtained prior to treatment, at time of surgery, and at 6 and 12 months post-surgery were examined by two different clonality assays: The HUMARA (HUMan Androgen Receptor) assay to estimate the incidence of early genetic damage by clonal proliferation, and microsatellite instability (MSI) testing to screen for LOH or defective DNA mismatch repair mechanisms. Clonal hematopoiesis was negative in 93.5% of the samples analyzed. Five patients showed a HUMARA-positive/MSI-negative pattern, and no patients showed a HUMARA-negative/MSI-positive pattern. With a median follow-up of 3.1 years, one patient in our study developed t-AML at 3 years 5 months after randomization. Our results indicate that clonal hematopoiesis assays performed within the 2 years following dose-intensive neoadjuvant therapy failed to identify an emerging clonal hematopoietic stem cell population. Longer clinical follow-up will be necessary to define better the positive predictive value of detecting clonal hematopoiesis in the HUMARA+/MSI- cases.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalBreast Cancer Research and Treatment
Volume119
Issue number2
DOIs
StatePublished - Jan 2010

Fingerprint

Neoadjuvant Therapy
Hematopoiesis
Microsatellite Instability
Breast Neoplasms
Neoplasms
Hematopoietic Stem Cells
Therapeutics
DNA Mismatch Repair
Second Primary Neoplasms
Incidence
Androgen Receptors
Random Allocation
Population

Keywords

  • Breast cancer
  • Clonal hematopoiesis
  • HUMARA
  • MSI
  • T-MN

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer : A Southwest Oncology Group study (S0012). / Slovak, Marilyn L.; Bedell, Victoria; Lew, Danika; Albain, Kathy S.; Ellis, Georgiana K.; Livingston, Robert B; Martino, Silvana; Perez, Edith A.; Hortobagyi, Gabriel N.; Sher, Dorie; Stock, Wendy.

In: Breast Cancer Research and Treatment, Vol. 119, No. 2, 01.2010, p. 391-398.

Research output: Contribution to journalArticle

Slovak, Marilyn L. ; Bedell, Victoria ; Lew, Danika ; Albain, Kathy S. ; Ellis, Georgiana K. ; Livingston, Robert B ; Martino, Silvana ; Perez, Edith A. ; Hortobagyi, Gabriel N. ; Sher, Dorie ; Stock, Wendy. / Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer : A Southwest Oncology Group study (S0012). In: Breast Cancer Research and Treatment. 2010 ; Vol. 119, No. 2. pp. 391-398.
@article{ecb115a3aec5446a911f2144274f7104,
title = "Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: A Southwest Oncology Group study (S0012)",
abstract = "A serious complication associated with breast cancer treatment is the increased risk for development of therapy-related myeloid neoplasms (t-MN). To determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis, and whether detection of clonal hematopoiesis could be used as an early marker for the subsequent development of t-MN, the Southwest Oncology Group designed a pilot clonality investigation to estimate the incidence of clonal hematopoiesis during and shortly after completion of the dose-intensive neoadjuvant regimens for high-risk breast cancer patients. Peripheral blood samples from 274 patients obtained prior to treatment, at time of surgery, and at 6 and 12 months post-surgery were examined by two different clonality assays: The HUMARA (HUMan Androgen Receptor) assay to estimate the incidence of early genetic damage by clonal proliferation, and microsatellite instability (MSI) testing to screen for LOH or defective DNA mismatch repair mechanisms. Clonal hematopoiesis was negative in 93.5{\%} of the samples analyzed. Five patients showed a HUMARA-positive/MSI-negative pattern, and no patients showed a HUMARA-negative/MSI-positive pattern. With a median follow-up of 3.1 years, one patient in our study developed t-AML at 3 years 5 months after randomization. Our results indicate that clonal hematopoiesis assays performed within the 2 years following dose-intensive neoadjuvant therapy failed to identify an emerging clonal hematopoietic stem cell population. Longer clinical follow-up will be necessary to define better the positive predictive value of detecting clonal hematopoiesis in the HUMARA+/MSI- cases.",
keywords = "Breast cancer, Clonal hematopoiesis, HUMARA, MSI, T-MN",
author = "Slovak, {Marilyn L.} and Victoria Bedell and Danika Lew and Albain, {Kathy S.} and Ellis, {Georgiana K.} and Livingston, {Robert B} and Silvana Martino and Perez, {Edith A.} and Hortobagyi, {Gabriel N.} and Dorie Sher and Wendy Stock",
year = "2010",
month = "1",
doi = "10.1007/s10549-009-0597-5",
language = "English (US)",
volume = "119",
pages = "391--398",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer

T2 - A Southwest Oncology Group study (S0012)

AU - Slovak, Marilyn L.

AU - Bedell, Victoria

AU - Lew, Danika

AU - Albain, Kathy S.

AU - Ellis, Georgiana K.

AU - Livingston, Robert B

AU - Martino, Silvana

AU - Perez, Edith A.

AU - Hortobagyi, Gabriel N.

AU - Sher, Dorie

AU - Stock, Wendy

PY - 2010/1

Y1 - 2010/1

N2 - A serious complication associated with breast cancer treatment is the increased risk for development of therapy-related myeloid neoplasms (t-MN). To determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis, and whether detection of clonal hematopoiesis could be used as an early marker for the subsequent development of t-MN, the Southwest Oncology Group designed a pilot clonality investigation to estimate the incidence of clonal hematopoiesis during and shortly after completion of the dose-intensive neoadjuvant regimens for high-risk breast cancer patients. Peripheral blood samples from 274 patients obtained prior to treatment, at time of surgery, and at 6 and 12 months post-surgery were examined by two different clonality assays: The HUMARA (HUMan Androgen Receptor) assay to estimate the incidence of early genetic damage by clonal proliferation, and microsatellite instability (MSI) testing to screen for LOH or defective DNA mismatch repair mechanisms. Clonal hematopoiesis was negative in 93.5% of the samples analyzed. Five patients showed a HUMARA-positive/MSI-negative pattern, and no patients showed a HUMARA-negative/MSI-positive pattern. With a median follow-up of 3.1 years, one patient in our study developed t-AML at 3 years 5 months after randomization. Our results indicate that clonal hematopoiesis assays performed within the 2 years following dose-intensive neoadjuvant therapy failed to identify an emerging clonal hematopoietic stem cell population. Longer clinical follow-up will be necessary to define better the positive predictive value of detecting clonal hematopoiesis in the HUMARA+/MSI- cases.

AB - A serious complication associated with breast cancer treatment is the increased risk for development of therapy-related myeloid neoplasms (t-MN). To determine whether dose-intensive adjuvant regimens for breast cancer induce genetic damage to hematopoietic stem cells, defined by the emergence of clonal hematopoiesis, and whether detection of clonal hematopoiesis could be used as an early marker for the subsequent development of t-MN, the Southwest Oncology Group designed a pilot clonality investigation to estimate the incidence of clonal hematopoiesis during and shortly after completion of the dose-intensive neoadjuvant regimens for high-risk breast cancer patients. Peripheral blood samples from 274 patients obtained prior to treatment, at time of surgery, and at 6 and 12 months post-surgery were examined by two different clonality assays: The HUMARA (HUMan Androgen Receptor) assay to estimate the incidence of early genetic damage by clonal proliferation, and microsatellite instability (MSI) testing to screen for LOH or defective DNA mismatch repair mechanisms. Clonal hematopoiesis was negative in 93.5% of the samples analyzed. Five patients showed a HUMARA-positive/MSI-negative pattern, and no patients showed a HUMARA-negative/MSI-positive pattern. With a median follow-up of 3.1 years, one patient in our study developed t-AML at 3 years 5 months after randomization. Our results indicate that clonal hematopoiesis assays performed within the 2 years following dose-intensive neoadjuvant therapy failed to identify an emerging clonal hematopoietic stem cell population. Longer clinical follow-up will be necessary to define better the positive predictive value of detecting clonal hematopoiesis in the HUMARA+/MSI- cases.

KW - Breast cancer

KW - Clonal hematopoiesis

KW - HUMARA

KW - MSI

KW - T-MN

UR - http://www.scopus.com/inward/record.url?scp=75049085476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75049085476&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0597-5

DO - 10.1007/s10549-009-0597-5

M3 - Article

C2 - 19851858

AN - SCOPUS:75049085476

VL - 119

SP - 391

EP - 398

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -